Camillo Massara

Financial Controller at CONTRAD SWISS

Camillo Massara is an accomplished financial professional with extensive experience in financial control and accounting. Currently serving as Financial Controller at CONTRAD SWISS since March 2015, Camillo previously held key positions at Isolin Trade & Invest, UMP Trading SA, and CNH. Responsibilities have included managing general ledgers, overseeing payables and receivables, and conducting financial reporting, budgeting, and variance analysis. Additional expertise includes administrative coordination and cost control from early career roles at ITTIERRE and Ermenegildo Zegna. Camillo has academic foundations in accounting and management, having studied at Università Cattolica del Sacro Cuore and participated in a management course in Bellinzona.

Location

Ticino, Switzerland

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


CONTRAD SWISS

CONTRAD SWISS is a dynamic Swiss-based pharmaceutical corporation revolutionizing the regenerative medicine landscape. Headquartered in Lugano, Contrad Swiss is the owner of proprietary SIGMOLECS® Technology which takes the current use of peptides as active ingredients a giant step forward. The company portfolio comprises medical devices and aesthetic products, positioned in the premium segment, delivering unparalleled value. SIGMOLECS® is a unique technology guiding cell behaviour for a wide range of treatments. It talks to cells in their own language, enabling more effective therapies. It is designed to work with various treatment methods, following the body's natural systems and also enhancing the penetration of other important molecules. This breakthrough technology, utilizing customized peptide sequences, is the driving force behind our specialized non-invasive product lines in Orthopaedics (500Line), Aesthetic Medicine (ACTV8 PRO), and in our targeted alleviating lotion (Egyfil), all supported by recently published peer-reviewed studies. The 500Line, powered by SIGMOLECS®, addresses unmet clinical needs in osteoarthritis and connective tissue pathology through non-invasive, rapid-acting formulations. Egyfil offers targeted relief for muscle & joint stiffness and discomfort. ACTV8 PRO is designed for regenerative aesthetic physicians. CONTRAD SWISS is signaling the future of regenerative medicine.


Employees

11-50

Links